Table 1.
Demographic characteristics of the study population included in the analyses by treatment and country.
| DHA-PQP | PA | ASAQ | AL | All | |||
|---|---|---|---|---|---|---|---|
| Age | N | 701 | 556 | 412 | 422 | 2091 | |
| Mean (range) | 8.6 (0–71) | 10.5 (1–62) | 7.9 (0–43) | 9.8 (0–64) | 9.2 (0–71) | ||
| <2 years | N (%) | 18 (2.6) | 7 (1.3) | 11 (2.7) | 8 (1.9) | 44 (2.1) | |
| 2–11 years | N (%) | 535 (76.3) | 361 (64.9) | 323 (78.4) | 286 (67.8) | 1505 (72.0) | |
| 12–18 years | N (%) | 122 (17.4) | 127 (22.8) | 68 (16.5) | 99 (23.5) | 416 (19.9) | |
| >18 years | N (%) | 26 (3.7) | 61 (11.0) | 10 (2.4) | 29 (6.9) | 126 (6.0) | |
| Gender | Female | N (%) | 342 (48.8) | 287 (51.6) | 187 (45.4) | 208 (49.3) | 1024 (49.0) |
| Male | N (%) | 359 (51.2) | 269 (48.4) | 225 (54.6) | 214 (50.7) | 1067 (51.0) | |
| Country | Burkina Faso | N (%) | 277 (39.5) | 198 (35.6) | 124 (30.1) | 213 (50.5) | 812 (38.8) |
| Guinea | N (%) | 134 (19.1) | 89 (16.0) | 126 (30.6) | 349 (16.7) | ||
| Mali | N (%) | 290 (41.4) | 269 (48.4) | 162 (39.3) | 209 (49.5) | 930 (44.5) | |
DHA-PQP, dihydroartemisinin-piperaquine; PA, pyronaridine-artesunate; ASAQ, artesunate-amodiaquine; AL, artemether-lumefantrine.